search only ICAHRIS™
Select Language

iBioSign™'s International Preventive Health Services (IPHS)™


It is a pleasure for the Maternal Health Intercultural Centre (MHIC™) to welcome you to this health portal where we have the most outstanding discoveries, globally, in the human microbiome and, in particular, the gut microbiota.

Enthusiastic and convinced of the importance of establishing preventive global health programmes, about ten years ago, we made relevant contributions in relation to early inflammatory processes. These contributions led to a better understanding of the effect of overweight and obesity on chronic diseases such as breast cancer, type 2 diabetes, musculoskeletal and cardiovascular system ailments[1-4].

Based upon these contributions, the identification and separation of a set of essential microorganisms, or biogenic clones, of the human microbiome, capable of colonizing the digestive tracts, was achieved over the course of the years. Specifically, today we refer to the restoration of your gut microbiota.

Consisting of bacteria, bacillus and a diverse population of microorganisms that inhabit your gut, the optimal gut microbiota is, at the present time, not only at the centre of the healthful and essential functioning of the digestive tracts but of the fundamental activities of our immune system, adipose tissue and our nervous system[1-4].

It is through this fine and exquisite network of interactions between the intestinal microbiota and a set of metabolic functions of our body that our current knowledge about nutritional genomics and, specifically, the nutriomics branch, that we have been able to specify the importance of establishing a diet and appropriate biogenic clones according to the health status of each individual.

In addition to a dietary regimen, there are several other factors that continuously affect the gut microbiota, inducing a process known as dysbiosis (not having an optimal gut microbiota[1-4]). This process of dysbiosis is due, amongst other things, to an imbalance of the microbial components in the digestive tract, which automatically places us in the path of myriad discomforts, some of which include poor digestion, constipation, heart burn, inscreased acidity, altered sleep, episodes of depression and, of course, the already well-known chronic-degenerative diseases which, sadly, today, we all too often know someone close, and perhaps yourself, suffering: Cancer, Lupus, Crohn's disease, Diabetes, Arthritis, Depression and Obesity[1-4].

Mindful of the importance of your life and that of your loved ones, today, we proudly share with you that, at our Centre (MHIC-Ottawa), we have good news for the recovery of your health and that of your family. Regardless of the disease condition that you are experiencing, we offer to add, in an important and accurate manner, to your current medical treatments in order to continue improving your health. We can achieve this through our International Preventive Health Services, here in Ottawa, Canada, under the direction of Dr Gabriel Pulido-Cejudo, the only scientist of international prestige who, today, has one-on-one contact with people with comprehensive preventive health issues obtaining effective results, some of which were recently shared in the framework of ICAHRIS Research's Fifteenth Anniversary.

With years of experience in various human diseases, and as an expert in the human microbiome, Dr Pulido has created a unique formulation consisting of a set of distinct bacilli and microorganisms that functions as an adjuvant biotic to your treatments with the aim of positively impacting your health in a forceful and precise way.

It is very important to note that our exclusive adjuvant biotic, nëliBIOM™, does not refer to products commonly identified as prebiotics or probiotics. In fact, it is a biota that you will not, at the moment, find anywhere else in the world. Only our members have access to all its benefits; we share some of the most important:

  • Improved digestive functioning.
  • Reach and maintain your optimal weight.
  • Decreased inflammatory processes related to diseases of the digestive tract such as Crohn's disease, Colitis, Ulcerative Colitis and carcinogenic processes.
  • Elimination of overweight and obesity.
  • Decreased and improved symptoms of mental illnesses such as depression, anxiety and those induced by injuries or concussions or strokes and those present in individuals with mental health conditions such as bipolarity / schizophrenia.
  • Improvement, decreased and optimised management of primary and secondary health problems in patients with type 2 diabetes.

At MHIC™, everyone is welcome - men, women and children - in search of cutting-edge medical science options, safe, reliable and effective ways to improve their health.

You, too, can receive the benefits of all our developments. Our International Preventive Health Services, based in Ottawa, Canada, is ready for your registration. Follow the link, below, to see complete information and details for planning your Health trip. Contact us today!

DO NOT LEAVE THE IMPORTANT TO LATER...<br/>We await you in Ottawa to find you your optimal health!

Enrol today!

Enrol today!


1. Pulido-Cejudo, G., El Abdaimi, K., Wang, C., Kar, B., Medina-Acevedo J., Cárdenas, J.M., Sarti-Gutierrez, E. J. and Martinez-Dominguez, M. (2004) Model building and quantitative analysis of a tandem immuno-capturing assay as a screening tool for breast cancer, International Journal of Oncology 25, 1365-1374.

2. Pulido-Cejudo, G., Miranda, H., El Abdaimi, K., Wang, C., Kar, B., Acevedo, J., Cárdenas, J. M., Sarti-Gutierrez, E. J. and Palacios, G. P. (2004) A monoclonal antibody driven biodiagnostic system for the quantitative screening of breast cancer, Biotechnology Letters 26, 1335-1339.

3. Pulido-Cejudo, G. and Pulido-Cejudo, A. (2009) Model on Potential Enhanced Virulence of Influenza A H1N1: A Possible Implication of 2',3 Diphosphoglycerate Pathways in Immediate Early Events Leading to Host / Viral Membrane Fusion. Prospective Clinical Benefit of Erythropoietin, enFarma Especial (2009) 38-45.

4. Pulido-Cejudo, G., Perez Urizar, J., Pulido-Cejudo, A., Riano, L., Cárdenas, J.M. and Becerril Luján, B. (2011) Obesity and Hyperobesity: The setting of an ongoing epidemic in landscape in North American children, enFarma 12:3, 46-52.

Granted Patents

  • Monoclonal Antibodies Directed Against NDP-Kinase. Inventor: G. Pulido-Cejudo. Canadian Patent 50,033; U.S. Patent Application No. 962,338, 1993.
  • Tandem Immuno-Assay For Cancer. Inventor: G. Pulido-Cejudo. Canadian Patent 2,303,598; U.S. Patent 6,521,415 B1/PCT, 2003.
  • Method and Compositions for Preventing or Reducing HIV Infection. Inventor: G. Pulido-Cejudo. Canadian Patent 2,303,591; U.S. Patent 6,406,701 B1/PCT, 2002.
  • A Monoclonal Antibody Against Estrogen-Stimulated Leucine Aminopeptidase. Inventor: G. Pulido-Cejudo. Canadian Patent 2,303,505; U.S. Patent 6,649,743B1/PCT, 2003.

Enrol today!